Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Droxidopa in NOH
NCT01132326Phase 3Completed
- Sponsor
- Chelsea Therapeutics International, Ltd.
- Start
- Jan 2009
- Primary completion
- Feb 2013
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, open-label, single-arm trial of droxidopa in Neurogenic Orthostatic Hypotension (nOH), sponsored by Chelsea Therapeutics International, Ltd. Primary endpoint: Patients With Treatment-emergent Adverse Events at 2 years. Started Jan 2009; status: completed.
02
Drugs
droxidopa
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on NCT01132326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01132326.